Novel Smith Chimeric Peptide Antigen and Its Application in Laboratory Diagnosis

Abstract

The invention discloses novel Smith chimeric peptide antigen and application thereof in experimental diagnosis. The antigen is a Sm chimeric peptide containing a plurality of antigen epitopes including three synthetic peptides of SmD-1, SmD-2 and SmB-1, wherein the Sm chimeric peptide antigen is coated on a solid phase carrier and can be used for detecting an anti-Sm antibody. The detecting method comprises an indirect ELISA (Enzyme Linked Immunosorbent Assay) method which coats the Sm chimeric peptide antigen on an elisa plate to prepare an indirect enzyme-linked immunodetection kit. The novel Smith chimeric peptide antigen disclosed by the invention is simple in preparation process, high in sensibility and specificity of detecting the anti-Sm antibody in systemic lupus erythematosus blood serum, good in repeatability, simple to operate, capable of being widely applied to clinical normal inspection and scientific research in a qualitative or quantitative manner, and has a good application value.

Description

technical field [0001] The invention belongs to the field of clinical immunity and medical experimental diagnosis, and in particular relates to a synthetic chimeric peptide (chimeric synthetic peptide) containing multiple dominant epitopes of Smith (Sm) protein antigens and its application in detecting anti-Sm in serum of systemic lupus erythematosus Antibody ELISA Kit. Background technique [0002] Systemic lupus erythematosus (SLE) is one of the most widespread and serious autoimmune diseases affecting the population, which can cause inflammation in multiple organs throughout the body. The disease develops latently, the course of the disease is protracted, repeated and exacerbated, and the clinical manifestations are complex and diverse, which is easily confused with other diseases, especially similar autoimmune diseases. Early detection, accurate diagnosis and timely treatment are decisive for improving the prognosis of SLE patients and reducing mortality. The current d...

AI Technical Summary

Problems solved by technology

But they have many disadvantages: 1. The protein is prone to denaturation during the crude extraction or purification process, the operation technology is difficult, the repeatability between batches is poor, and the price is expensive; 2. Due to the influence of the secondary space structure of the protein or polypeptide, its Some of the contained antigenic determinants cannot be exposed on the surface of protein molecules and are bound by antibodies; 3. Due to the high content of amino acids in non-antigenic determinants, they may combine with other non-specific antibodies, resulting in a decrease in diagnostic specificity

In this way, if only any synthetic peptide containing a single dominant epitope is used like some current commercial kits, a considerable part of the Sm antibody subtype will be missed, resulting in insufficient sensitivity

However, it is technically difficult to coat the above three synthetic peptides on the ELISA plate at the same time because the short peptides compete with each other for limited coating sites.

Images